This phase III trial is evaluating the safety and effectiveness of a chemotherapy in combination with a cancer treatment known as Azacitidine (Vidaza) in patients with newly diagnosed higher-risk myelodysplastic syndrome.
This trial is treating patients with Higher-Risk Myelodysplastic Syndrome.
This is a systemic therapy trial.
You may be excluded from this trial if:
- You have a certain disease or psychological condition.
- You have had certain treatments, surgical procedures or drugs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)
Eligible patients will be randomised to receive either an oral placebo or oral venetoclax once daily (QD) (Days 1-14) in combination with (Azacitidine) AZA QD (Days 1-7) of each 28 day cycle.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More